



Novel Glycan targeting therapy for Pancreatic Cancer

rBC2LCN lectin staining for pancreatic adenocarcinoma



Lectin-Drug conjugate: "LDC"




Applying 'LDC' for cancer treatment


rBC2LCN lectin (Glycan binding protein) reactivity to cancer cells; 69/69 (100%) positive in clinical PDAC patients

MTT assay anti-cancer effect *in vitro*


Capan-1 (**Positive** for rBC2LCN)




1.04 pg/ml



Improve the survival of PDAC dissemination model



Target cancer related glycan using "lectin"



This is the first report applying lectin as a drug carrier. Cell surface H type 1/3/4 glycan of pancreatic cancer recognized by rBC2LCN lectin seems as a druggable target. Our novel biological agent "LDC" enables 1,000 times stronger cytotoxicity than antibody-based medicine *in vitro* and may provide promising anti-cancer effect for patients with pancreatic cancer. LDC is now preparing for first-in-human test.